Biologics in Inflammatory Bowel Disease
Foreword B i o l o g i c s of I B D
Gary W. Falk, MD, MS Consulting Editor
The therapy of inflammatory bowel disease has changed dramatically in recent years with the advent of biologic therapy. Whereas therapy of inflammatory bowel disease once involved a simple menu of choices, such as corticosteroids, 5-ASA compounds, azathioprine, and surgery, the introduction of biologics has altered clinical practice. Current questions for both patients and physicians include the following: 1. 2. 3. 4. 5. 6.
When should biologic therapy be commenced? What biologic is optimal? What is the correct dosing? How should therapy be monitored? What are the risks of therapy including infection and neoplasia? Are there new and better options on the horizon?
Ed Loftus from the Mayo Clinic has brought together an outstanding group of contributing authors to address these and other questions related to biologics in inflammatory bowel disease. These state-of-the-art articles will provide practical guidance for you as you navigate the rapidly changing world of inflammatory bowel disease therapy. Gary W. Falk, MD, MS Division of Gastroenterology Hospital of the University of Pennsylvania University of Pennsylvania Perelman School of Medicine 9 Penn Tower One Convention Avenue Philadelphia, PA 19104, USA E-mail address: [email protected]
Gastroenterol Clin N Am 43 (2014) xiii http://dx.doi.org/10.1016/j.gtc.2014.07.001 gastro.theclinics.com 0889-8553/14/$ – see front matter Ó 2014 Elsevier Inc. All rights reserved.
Foreword B i o l o g i c s of I B D
Gary W. Falk, MD, MS Consulting Editor
The therapy of inflammatory bowel disease has changed dramatically in recent years with the advent of biologic therapy. Whereas therapy of inflammatory bowel disease once involved a simple menu of choices, such as corticosteroids, 5-ASA compounds, azathioprine, and surgery, the introduction of biologics has altered clinical practice. Current questions for both patients and physicians include the following: 1. 2. 3. 4. 5. 6.
When should biologic therapy be commenced? What biologic is optimal? What is the correct dosing? How should therapy be monitored? What are the risks of therapy including infection and neoplasia? Are there new and better options on the horizon?
Ed Loftus from the Mayo Clinic has brought together an outstanding group of contributing authors to address these and other questions related to biologics in inflammatory bowel disease. These state-of-the-art articles will provide practical guidance for you as you navigate the rapidly changing world of inflammatory bowel disease therapy. Gary W. Falk, MD, MS Division of Gastroenterology Hospital of the University of Pennsylvania University of Pennsylvania Perelman School of Medicine 9 Penn Tower One Convention Avenue Philadelphia, PA 19104, USA E-mail address: [email protected]
Gastroenterol Clin N Am 43 (2014) xiii http://dx.doi.org/10.1016/j.gtc.2014.07.001 gastro.theclinics.com 0889-8553/14/$ – see front matter Ó 2014 Elsevier Inc. All rights reserved.
